<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797767</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121403</org_study_id>
    <secondary_id>NCI-2021-01379</secondary_id>
    <secondary_id>10793</secondary_id>
    <nct_id>NCT04797767</nct_id>
  </id_info>
  <brief_title>Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms</brief_title>
  <official_title>A Phase 1 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial finds the best dose and side effects of venetoclax in combination with&#xD;
      cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in&#xD;
      treating patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax&#xD;
      may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell&#xD;
      survival. Chemotherapy drugs, such as cladribine, cytarabine, and mitoxantrone, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Giving venetoclax with CLAG-M may&#xD;
      kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      This is a dose-escalation study of venetoclax.&#xD;
&#xD;
      Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if&#xD;
      peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine&#xD;
      on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days&#xD;
      1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone,&#xD;
      and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of venetoclax in combination with CLAG-M</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>After 2 cycles (each cycle is approximately 35 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of allogeneic hematopoietic cell transplant</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <condition>Myeloid Neoplasm</condition>
  <condition>Relapsed Acute Biphenotypic Leukemia</condition>
  <condition>Relapsed Acute Myeloid Leukemia</condition>
  <condition>Relapsed Mixed Phenotype Acute Leukemia</condition>
  <condition>Relapsed Myeloid Neoplasm</condition>
  <condition>Refractory Acute Biphenotypic Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Mixed Phenotype Acute Leukemia</condition>
  <condition>Refractory Myeloid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (CLAG-M, venetoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, venetoclax)</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>2CDA</other_name>
    <other_name>CdA</other_name>
    <other_name>Cladribina</other_name>
    <other_name>Leustat</other_name>
    <other_name>Leustatin</other_name>
    <other_name>Leustatine</other_name>
    <other_name>RWJ-26251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, venetoclax)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, venetoclax)</arm_group_label>
    <other_name>Dihydroxyanthracenedione</other_name>
    <other_name>Mitozantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Granulocyte Colony-Stimulating Factor</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Treatment (CLAG-M, venetoclax)</arm_group_label>
    <other_name>Recombinant Colony-Stimulating Factor 3</other_name>
    <other_name>rhG-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (CLAG-M, venetoclax)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia (per the World Health Organization [WHO] 2016 classification)&#xD;
             or high-grade myeloid neoplasm (&gt;= 10% myeloid blasts in peripheral blood or marrow)&#xD;
&#xD;
               -  Newly diagnosed patients must have adverse risk disease as per the European&#xD;
                  LeukemiaNet 2017 guidelines&#xD;
&#xD;
               -  Relapsed/refractory patients must require first or subsequent salvage therapy&#xD;
&#xD;
               -  Patients with biphenotypic or mixed phenotype acute leukemia are eligible&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Aspartate transaminase (AST) and alanine transaminase (ALT) =&lt; 3.0 X upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
             non-hepatic origin)&#xD;
&#xD;
          -  Subject must have adequate renal function as demonstrated by a creatinine clearance &gt;=&#xD;
             30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine&#xD;
             collection&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 45%, assessed by multigated acquisition&#xD;
             (MUGA) or echocardiogram (ECHO) within 3 months prior to study day 0 or after most&#xD;
             recent anthracycline administration if appropriate&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) =&lt; 2&#xD;
&#xD;
          -  Treatment-related mortality (TRM) score &lt; 13.1&#xD;
&#xD;
          -  Female subjects of childbearing potential must have negative results for pregnancy&#xD;
             test&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  White blood cell count in peripheral blood must be &lt; 25,000/ul prior to initiation of&#xD;
             study therapy (CLAG-M plus venetoclax). Cytoreduction with hydroxyurea and/or&#xD;
             cytarabine (e.g., 500 mg/m^2 per dose) is allowed to decrease the risk of tumor lysis&#xD;
             syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia or chronic myeloid leukemia in myeloid blast crisis&#xD;
&#xD;
          -  Known active central nervous system (CNS) involvement with acute myeloid leukemia&#xD;
             (AML)&#xD;
&#xD;
          -  Concomitant illness associated with a likely survival of &lt; 1 year&#xD;
&#xD;
          -  Active systemic infection, unless disease is under treatment with antimicrobials and&#xD;
             considered controlled or stable; patients with fever thought to be likely secondary to&#xD;
             leukemia are eligible. Patients with chronic hepatitis B virus (HBV) or hepatitis C&#xD;
             (HCV) requiring treatment would be excluded. Note: subjects with serologic evidence of&#xD;
             prior vaccination to HBV (i.e. hepatitis B surface [HBs] antigen negative-, anti-HBs&#xD;
             antibody positive and anti-hepatitis B core [HBc] antibody negative) or positive&#xD;
             anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate&#xD;
&#xD;
          -  Active or clinically significant (or symptomatic) cardiac disease, including active&#xD;
             coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other&#xD;
             than beta blockers or digoxin within the last 3 months, unstable angina (anginal&#xD;
             symptoms at rest), new-onset angina within 3 months before randomization, or&#xD;
             myocardial infarction within 6 months before study day 0&#xD;
&#xD;
          -  Known hypersensitivity to any study drug&#xD;
&#xD;
          -  Pregnancy or lactation because of the unknown risks of this combination&#xD;
&#xD;
          -  Concurrent treatment with any other investigational agent&#xD;
&#xD;
          -  Subject is known to be positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Treatment with any of the following within 7 days prior to the first dose of&#xD;
             venetoclax&#xD;
&#xD;
               -  Steroid therapy for anti-neoplastic intent&#xD;
&#xD;
          -  Administration or consumption of any of the following within 3 days prior to the first&#xD;
             dose of venetoclax:&#xD;
&#xD;
               -  Grapefruit or grapefruit products&#xD;
&#xD;
               -  Seville oranges (including marmalade containing Seville oranges)&#xD;
&#xD;
               -  Star fruit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary-Beth M. Percival</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Quach</last_name>
    <phone>206.606.8311</phone>
    <email>kquach@seattlecca.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary-Beth M. Percival</last_name>
    <phone>206.606.1320</phone>
    <email>mperciva@seattlecca.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kim Quach</last_name>
      <phone>206-606-8311</phone>
      <email>kquach@seattlecca.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary-Beth M. Percival</last_name>
      <phone>206-606-1320</phone>
      <email>mperciva@seattlecca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mary-Beth M. Percival</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

